The Medical Letter on Drugs and Therapeutics
FROM
ISSUE
1417
Omalizumab (Xolair) for Chronic Urticaria
The full article is available to subscribers Subscriber Login   

Omalizumab (Xolair) is a recombinant humanized monoclonal anti-IgE antibody currently approved by the FDA for treatment of moderate to severe persistent allergic asthma.1 It has been used off-label for treatment of allergic rhinitis and food allergies. Recently the results of a phase III clinical trial indicated that omalizumab may be effective in treating chronic urticaria as well.2

STANDARD TREATMENT — Second-generation H1-antihistamines are the current standard of care for chronic urticaria (hives that persist for ≥6 weeks).3,4 However, many patients do not respond to usual doses and some do not respond to up-dosing (off-label), even at 4 times the usual dose.5,6 Second-line agents include first-generation ... more       Show References Hide References

The Medical Letter is a subscriber-funded nonprofit organization that publishes critical appraisals of new prescription drugs and comparative reviews of drugs for common diseases.

Would you like to read the rest of this article?  Gain access below.

Subscribe
Subscriptions to The Medical Letter on Drugs and Therapeutics include:
  • Print version published and mailed biweekly (26 issues/year)
  • Immediate Online access to current issue and archives from 1988 to the present
  • Mobile access to our mobile site and free apps for iOS, Android and Kindle
  • FREE online per issue CME/CE
Free trial offer
3 Free Issues of The Medical Letter on Drugs and Therapeutics mailed to your home or office PLUS online access.
Try a Free Trial Subscription
Purchase this article:
Title: Omalizumab (Xolair) for Chronic Urticaria
Article code: 1417b
 Electronic, downloadable article - $25